Phio Pharmaceuticals Corp.
PHIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePhio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. The $12.5M market capitalization puts PHIO squarely in micro-cap range for its industry. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Market Cap
$12.5M
Beta
0.80
P/E (TTM)
—
P/E (Fwd)
-1.77
EPS (TTM)
$-1.29
EPS (Fwd)
$-0.61
ROE
-113.7%
ROA
-65.8%
Cash
$13.0M
Total Debt
$0
Free CF
-$7.7M
52W Change
-55.7%
Annual Financials
Cash vs Debt
Where PHIO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PHIO finished 0.89% above its 150-day moving average ($1.12) and 0.00% above its 200-day moving average ($1.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PHIO overbought or oversold?
At the September 3, 2026 close, PHIO's RSI(14) was 54.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Phio Pharmaceuticals Corp. reports $13.0M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$7.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -113.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PHIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.